2013-04677. Agency Information Collection Activities; Proposed Collection; Comment Request; Mammography Quality Standards Act Requirements  

  • Start Preamble

    AGENCY:

    Food and Drug Administration, HHS.

    ACTION:

    Notice.

    SUMMARY:

    The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on Start Printed Page 13682the estimated reporting, recordkeeping, and third-party disclosure burden associated with the Mammography Quality Standards Act requirements.

    DATES:

    Submit either electronic or written comments on the collection of information by April 29, 2013.

    ADDRESSES:

    Submit electronic comments on the collection of information to http://www.regulations.gov. Submit written comments on the collection of information to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number found in brackets in the heading of this document.

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    Daniel Gittleson, Office of Information Management, Food and Drug Administration, 1350 Piccard Dr., PI50-400B, Rockville, MD 20850, 301-796-5156, Daniel.Gittleson@fda.hhs.gov.

    End Further Info End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    Under the PRA (44 U.S.C. 3501-3520), Federal Agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. “Collection of information” is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes Agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal Agencies to provide a 60-day notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collection of information set forth in this document.

    With respect to the following collection of information, FDA invites comments on these topics: (1) Whether the proposed collection of information is necessary for the proper performance of FDA's functions, including whether the information will have practical utility; (2) the accuracy of FDA's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology.

    Mammography Quality Standards Act Requirements—21 CFR Part 900 (OMB Control Number 0910-0309)—Extension

    The Mammography Quality Standards Act requires the establishment of a Federal certification and inspection program for mammography facilities; regulations and standards for accreditation and certification bodies for mammography facilities; and standards for mammography equipment, personnel, and practices, including quality assurance. The intent of these regulations is to assure safe, reliable, and accurate mammography on a nationwide level. Under the regulations, as a first step in becoming certified, mammography facilities must become accredited by an FDA-approved accreditation body (AB). This requires undergoing a review of their clinical images and providing the AB with information showing that they meet the equipment, personnel, quality assurance and quality control standards, and have a medical reporting and recordkeeping program, a medical outcomes audit program, and a consumer complaint mechanism. On the basis of this accreditation, facilities are then certified by FDA or an FDA-approved State certification agency and must prominently display their certificate. These actions are taken to ensure safe, accurate, and reliable mammography on a nationwide basis.

    The following sections of Title 21 of the Code of Federal Regulations (CFR) are not included in the burden tables because they are considered usual and customary practice and were part of the standard of care prior to the implementation of the regulations. Therefore, they resulted in no additional burden: 21 CFR 900.12(c)(1) and (c)(3) and 21 CFR 900.3(f)(1). Section 900.24(c) was also not included in the burden tables because if a certifying State had its approval withdrawn, FDA would take over certifying authority for the affected facilities. Because FDA already has all the certifying State's electronic records, there wouldn't be an additional reporting burden.

    We have rounded numbers in the “Total Hours” column in all three burden tables. (Where the number was a portion of one hour, it has been rounded to 1 hour. All other “Total Hours” have been rounded to the nearest whole number.)

    We do not expect any respondents for § 900.3(c) because all four ABs are approved until April 2020.

    FDA estimates the burden of this collection of information as follows:

    Table 1—Estimated Annual Reporting Burden

    Activity/21 CFR Section/FDA Form No.Number of respondentsNumber of responses per respondentTotal annual responsesAverage burden per responseTotal hours 1Total capital costsTotal operating & maintenance costs
    Notification of intent to become an AB—900.3(b)(1)0.3310.3311
    Application for approval as an AB; full 2—900.3(b)(3)0.3310.33320106$10,000
    Application for approval as an AB; limited 3—900.3(b)(3)51530150
    AB renewal of approval—900.3(c)010151
    AB application deficiencies—900.3(d)(2)0.110.1303
    AB resubmission of denied applications—900.3(d)(5)0.110.1303
    Letter of intent to relinquish accreditation authority—900.3(e)0.110.111
    Summary report describing all facility assessments—900.4(f)330133072,310$77,600
    AB reporting to FDA; facility 4—900.4(h)8,65418,65418,6544,327
    AB reporting to FDA; AB 5—900.4(h)5151050
    AB financial records—900.4(i)(2)1111616
    Start Printed Page 13683
    Former AB new application—900.6(c)(1)0.110.1606
    Reconsideration of accreditation following appeal—900.15(d)(3)(ii)11122
    Application for alternative standard—900.18(c)21224
    Alternative standard amendment—900.18(e)10110110
    Certification agency application—900.21(b)0.3310.33320106$208
    Certification agency application deficiencies—900.21(c)(2)0.110.1303
    Certification electronic data transmission—900.22(h)520010000.08383$30,000
    Changes to standards—900.22(i)2123060$20
    Certification agency minor deficiencies—900.24(b)1113030
    Appeal of adverse action taken by FDA—900.25(a)0.210.2163
    Inspection fee exemption—FDA Form 342270017000.25175
    Total11,77740,00082,155
    1 Total hours have been rounded.
    2 One time burden.
    3 Refers to accreditation bodies applying to accredit specific full-field digital mammography units.
    4 Refers to the facility component of the burden for this requirement.
    5 Refers to the AB component of the burden for this requirement.

    Table 2—Estimated Annual Recordkeeping Burden

    Activity/21 CFR SectionNo. of recordkeepersNo. of records per recordkeeperTotal annual recordsAverage burden per recordkeepingTotal hours 1Total capital costsTotal operating and maintenance costs
    AB transfer of facility records—900.3(f)(1)0.110.101
    Consumer complaints system; AB—900.4(g)51515
    Documentation of interpreting physician initial requirements—900.12(a)(1)(i)(B)(2)871878696
    Documentation of interpreting physician personnel requirements—900.12(a)(4)8,654434,616134,616
    Permanent medical record—900.12(c)(4)8,65418,65418,654$28,000
    Procedures for cleaning equipment—900.12(e)(13)8,65452450,0080.08337,351
    Audit program—900.12(f)8,65418,65416138,464
    Consumer complaints system; facility—900.12(h)(2)8,654217,308117,308
    Certification agency conflict of interest—900.22(a)51515
    Processes for suspension and revocation of certificates—900.22(d)51515
    Processes for appeals—900.22(e)51515
    Processes for additional mammography review—900.22(f)51515
    Processes for patient notifications—900.22(g)31313$30
    Evaluation of certification agency—900.2351520100
    Appeals—900.25(b)51515
    Total237,22328,00030
    1 Total hours have been rounded.
    Start Printed Page 13684

    Table 3—Estimated Annual Third-Party Disclosures 1

    Activity/21 CFR SectionNumber of respondentsNumber of disclosures per respondentTotal annual disclosuresAverage burden per disclosureTotal hours 2Total operating and maintenance costs
    Notification of facilities that AB relinquishes its accreditation—900.3(f)(2)0.110.120020$50
    Clinical images; facility 2—900.4(c), 900.11(b)(1), and 900.11(b)(2)2,88512,8851.444,154
    Clinical images; AB 3—900.4(c)5154162,080230,773
    Phantom images; facility 2—900.4(d), 900.11(b)(1), and 900.11(b)(2)2,88512,8850.722,077
    Phantom images; AB 3—900.4(d)5152081,040
    Annual equipment evaluation and survey; facility 2—900.4(e), 900.11(b)(1), and 900.11(b)(2)8,65418,65418,6548,654
    Annual equipment evaluation and survey; AB 3—900.4(e)5151,7308,650
    Provisional mammography facility certificate extension application—900.11(b)(3)0100.51
    Mammography facility certificate reinstatement application—900.11(c)312131251,56024,000,000
    Lay summary of examination—900.12(c)(2)8,6545,08544,005,5900.0833,652,464
    Lay summary of examination; patient refusal 4—900.12(c)(2)871870.544
    Report of unresolved serious complaints—900.12(h)(4)20120120
    Information regarding compromised quality; facility 2—900.12(j)(1)201202004,000300
    Information regarding compromised quality; AB 3—900.12(j)(1)201203206,400600
    Patient notification of serious risk—900.12(j)(2)51510050019,375
    Reconsideration of accreditation—900.15(c)515210
    Notification of requirement to correct major deficiencies—900.24(a)0.410.42008068
    Notification of loss of approval; major deficiencies—900.24(a)(2)0.1510.151001525.50
    Notification of probationary status—900.24(b)(1)0.310.32006051
    Notification of loss of approval; minor deficiencies—900.24(b)(3)0.1510.151001525.50
    Total3,691,84224,259,921
    1 There are no capital costs associated with this collection of information.
    2 Total hours have been rounded.
    Start Signature

    Dated: February 22, 2013.

    Leslie Kux,

    Assistant Commissioner for Policy.

    End Signature End Supplemental Information

    [FR Doc. 2013-04677 Filed 2-27-13; 8:45 am]

    BILLING CODE 4160-01-P

Document Information

Comments Received:
0 Comments
Published:
02/28/2013
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice.
Document Number:
2013-04677
Dates:
Submit either electronic or written comments on the collection of information by April 29, 2013.
Pages:
13681-13684 (4 pages)
Docket Numbers:
Docket No. FDA-2013-N-0134
PDF File:
2013-04677.pdf
Supporting Documents:
» MQSA Ref 34 Eastern Research Group Inc. - Baseline Quality Measures
» MQSA Ref 31 - ACR BI-RADS pp 7-8
» MQSA Ref 27 - Ho 2014 AJR
» MQSA Ref 22 - Transcript of Sept 29 2006 - 2nd part
» MQSA Ref 22 - Transcript of Sept 28 2006 - 3rd part
» MQSA Ref 22 - Transcript of Sept 28 2006 - 2nd part
» MQSA Ref 21 - Dense Breast Info website
» MQSA Ref 20 - NMQAAC summary 2011
» MQSA Ref 19 - Berg 2008 JAMA
» MQSA Ref 17 - Kolb 2002 Radiol